Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 1,301–1,400 of 2,932
Sabino, R., Antunes, F., Araujo, R., Bezerra, A. R., Brandão, J. C., Carneiro, C., Carvalho, A., Carvalho, D., Conceição, I. M., Medeiros, F. C., et al. (2025) · Mycopathologia · doi:10.1007/s11046-025-00981-3 · Cited by 18
“…is the main agent responsible for mucosal disease, with an estimated global burden of ~ 134,000,000 recurrent vulvovaginal candidiasis [9], and more than one million annual incidence of oral or esophageal candidiasis worldwide associated with human immunodeficiency virus (HIV) infection [10].”
Bloch, A., Bogiel, T., Prażyńska, M. B., & Gospodarek-Komkowska, E. (2025) · Methods and Protocols · doi:10.3390/mps8050098 · Cited by 11
“Global socio-economic development, environmental changes, and pro-ecological practices significantly influence the variability in the occurrence and spread of fungal diseases [1].”
Metal-based triazoles as a medical marvel of the modern era: a comprehensive review
Haseeb, K., Mustafa, M. H., Zafar, W., Hassan, A. U., CHOHAN, Z. H., & Sumrra, S. H. (2026) · RSC Advances · doi:10.1039/d5ra07766d · Cited by 13
Murine model to follow hyphal development in invasive pulmonary aspergillosis
Szigeti, Z. M., Tálas, L., Palicz, Z., Szentesi, P., Hargitai, Z., Csernoch, L. J., Balla, J., Pócsi, I., Bánfalvi, G., & Szemán-Nagy, G. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-8800-4 · Cited by 8
“Recent global estimates have found that fungal diseases affect over 1 billion people, among them three million cases of chronic pulmonary aspergillosis (Bongomin et al. 2017).”
BackgroundResistance to Nano-Based Antifungals Is Mediated by Biomolecule Coronas
Siemer, S., Westmeier, D., Vallet, C., Becker, S., Voskuhl, J., Ding, G., Thines, E., Stauber, R. H., & Knauer, S. K. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b12175 · Cited by 10
RetractedInvasive pulmonale Aspergillose
Matthews, H., Rohde, H., Wichmann, D., & Kluge, S. (2019) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0817-7432 · Cited by 9
Rattani, S., Farooqi, J. Q., Hussain, A. S., & Jabeen, K. (2021) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003161 · Cited by 10
“Neonatal candidemia has also been on the rise globally.(4,7,8) Studies from Pakistan reported non-albicans Candida species to be causative agents in 73.”
BackgroundPrecision Therapy for Invasive Fungal Diseases
Märtson, A., Alffenaar, J. C., Brüggemann, R. J. M., & Hope, W. W. (2021) · Journal of Fungi · doi:10.3390/jof8010018 · Cited by 11
“Mortality in real-world settings is generally 20–50% but may be higher in specific contexts [2].”
BackgroundInácio, M. M., Cruz-Leite, V. R. M., Moreira, A. L. E., Mattos, K., Paccez, J. D., Ruiz, O. H., Venturini, J., Melhem, M. D. S. C., Paniago, A. M. M., Soares, C. M. D. A., et al. (2022) · Pathogens · doi:10.3390/pathogens11050569 · Cited by 9
Leepattarakit, T., Tulyaprawat, O., & Ngamskulrungroj, P. (2022) · Journal of Fungi · doi:10.3390/jof8100983 · Cited by 9
“Candida species are the most common cause of invasive fungal infections, affecting around three-quarters of a million patients per year [1].”
BackgroundSiddiqui, R., Mendiratta, D. K., Siddiqui, A. F., & Rukadikar, A. R. (2023) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1479_22 · Cited by 11
“6 million people worldwide to have suffered from serious fungal diseases that can even be fatal.[1]”
BackgroundPfaller, M. A., Carvalhaes, C. G., Deshpande, L. M., Rhomberg, P. R., & Castanheira, M. (2023) · Journal of Fungi · doi:10.3390/jof9060608 · Cited by 10
Steffan, B. N., Calise, D. G., Park, S. C., Niu, M., Yang, J., Hammock, B. D., Jones, M., Steele, C. H., & Keller, N. P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1173544 · Cited by 8
Liu, Y., Yang, Y., Wei, J., Wang, T., Li, L.-Z., & Shen, Z. (2023) · Aerosol Science and Technology · doi:10.1080/02786826.2023.2283480 · Cited by 8
“It has been reported that the size and shape of fungal particles may be very important in determining their specific biological responses, and the prevalence of invasive fungal diseases has increased considerably over the past two decades (Bongomin et al. 2017; Oberd € orster et al. 1992).”
BackgroundAtalay, V. E., & Asar, S. (2024) · The European Chemistry and Biotechnology Journal · doi:10.62063/ecb-15 · Cited by 10
“Fungal infections affect more than one billion people worldwide each year, with more than 1.6 million infected cases resulting in death (Bongomin et al., 2017; Gupta et al., 2012).”
BackgroundInfluentialWang, X., Li, S., Zhu, M., et al. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09014-8 · Cited by 8
“According to a survey of the prevalence of fungal diseases in multiple countries, more than 3 million people a year now contract pulmonary mycosis, a 41-fold increase in 32 years [2].”
BackgroundBowen, J. I., Zhong, X., Gao, K., Reed, B., Crump, M. P., Wang, L., & Willis, C. L. (2024) · Chemical Science · doi:10.1039/d4sc00720d · Cited by 8
Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs
Schmidlin, K., Apodaca, S., Newell, D., Sastokas, A., Kinsler, G., & Geiler‐Samerotte, K. (2024) · eLife · doi:10.7554/elife.94144 · Cited by 18
“FLU is a first line of defense against yeast infections, but over the past two decades diverse resistant mutations have been identified ( Bongomin et al., 2017 ; Osset-Trénor et al., 2023 ; Rybak et al., 2022 ).”
de Souza, C. S., Lopes, V. R. D. C., Barcellos, G. D. C., Alexandrino-Júnior, F., Neves, P., Patricio, B. F. D. C., Rocha, H. V. A., Bom, A. P. D. A., & Figueiredo, A. (2024) · Journal of Fungi · doi:10.3390/jof10050344 · Cited by 9
“Forecasts within this group portend a mortality toll surpassing 1.6 million deaths, which parallels the concerning impact of tuberculosis and concurrently manifests a threefold malaria-associated fatality [3].”
BackgroundInfluentialIsmail, S. H. H., Hamdy, R., Altaie, A. M., Fayed, B. E., Dakalbab, S., El‐Awady, R., & Soliman, S. S. M. (2024) · Mycologia · doi:10.1080/00275514.2024.2363730 · Cited by 8
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year (Baron 1996; Walsh and Dixon 1996), primarily in those with compromised immunity (Bongomin et al. 2017).”
InfluentialExophiala species in household environments and their antifungal resistance profile
Kondori, N., Jaén‐Luchoro, D., Karlsson, R., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-68166-4 · Cited by 8
Bouqellah, N. A., Abdel‐Hafez, L. J. M., Mostafa, I. Y., & Faraag, A. H. I. (2024) · International Microbiology · doi:10.1007/s10123-024-00591-x · Cited by 10
“Infections caused by invasive fungi, such as candidiasis, aspergillosis, and cryptococcosis , can be life-threatening for individuals with weakened immune systems (Perlin et al. 2015; Bongomin et al. 2017; Rodrigues and Nosanchuk 2020).”
Fungal disease incidence and prevalence in Iraq – Preliminary estimates
Mohammad, K. A., Ismail, H. M., Shekhany, K. A. M., Yashooa, R. K., Younus, D. A., Abdullah, S. K., Al-Attraqchi, A. A. F., Aldabbagh, R., & Denning, D. W. (2024) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2024.101516 · Cited by 15
“To account for different annual incidence in all patient groups we considered utilizing the average global estimate of 5.79 / 100,000[7] resulting in an incidence of 2142.”
InfluentialSelf-citationGarvey, M., Kremer, T. A., & Rowan, N. J. (2025) · Journal of Applied Microbiology · doi:10.1093/jambio/lxaf005 · Cited by 12
Santiago-Tirado, F. H., Klein, R. S., & Doering, T. L. (2019) · Current Protocols in Microbiology · doi:10.1002/cpmc.78 · Cited by 10
Bongomin, F., Kwizera, R., Atukunda, A., & Kirenga, B. (2019) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2019.07.001 · Cited by 8
“CPA is estimated to affect approximately three million people worldwide [3].”
BackgroundSelf-citationLinking calcium signaling and mitochondrial function in fungal drug resistance
Bowyer, P., Bromley, M., & Denning, D. W. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920497117 · Cited by 10
Self-citationde Oliveira, F. F. M., Paredes, V., de Sousa, H. R., Moura, Á. N. D., Riasco-Palacios, J., Casadevall, A., Felipe, M. S. S., & Nicola, A. M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02930 · Cited by 9
Bongomin, F., Garcez, T. P., & Denning, D. W. (2020) · Medical Mycology · doi:10.1093/mmy/myaa026 · Cited by 9
Self-citationAnti-Infective Antibody-Derived Peptides Active against Endogenous and Exogenous Fungi
Ciociola, T., Giovati, L., Conti, S., & Magliani, W. (2021) · Microorganisms · doi:10.3390/microorganisms9010143 · Cited by 8
Enhancing the chemical transformation of Candida parapsilosis
Németh, T., Nosanchuk, J. D., Vágvölgyi, C., & Gácser, A. (2021) · Virulence · doi:10.1080/21505594.2021.1893008 · Cited by 10
Zareshahrabadi, Z., Karami, F., Taghizadeh, S., Iraji, A., Amani, A. M., Motamedi, M., & Zomorodian, K. (2021) · Journal of nano research · doi:10.4028/www.scientific.net/jnanor.67.55 · Cited by 11
“Cryptococcus species are another encapsulated yeasts and considered as the main causative agent of meningitis in HIV-positive adults which cause about 180,000 deaths annually [18; 21].”
BackgroundRepurposing benzimidazoles to fight Cryptococcus
de Oliveira, H. C., & Rodrigues, M. L. (2021) · Fungal Biology Reviews · doi:10.1016/j.fbr.2021.04.002 · Cited by 10
Ghandhi, L., Bidula, S. M., Pask, C. M., Lord, R. M., & McGowan, P. C. (2021) · ChemMedChem · doi:10.1002/cmdc.202100159 · Cited by 6
Samuel, S. S., & Veeramani, A. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95458 · Cited by 8
“Many fungi are of great environmental and medical importance and its study is termed as Mycology [4].”
BackgroundSatała, D., Zelazna, A., Satała, G., Bukowski, M., Zawrotniak, M., Rąpała‐Kozik, M., & Kozik, A. (2021) · Acta Biochimica Polonica · doi:10.18388/abp.2020_5959 · Cited by 11
“A large body of evidence has proven that the pathogenic nature of this yeast is primarily a consequence of significant impairment of the host immune mechanisms (Bongomin et al., 2017; Ho et al., 2021).”
BackgroundPneumocystis Pneumonia: Pitfalls and Hindrances to Establishing a Reliable Animal Model
Chesnay, A., Paget, C., Heuzé‐Vourc'h, N., Baranek, T., & Désoubeaux, G. (2022) · Journal of Fungi · doi:10.3390/jof8020129 · Cited by 7
“jirovecii is the second most common fungal agent among invasive fungal infections [6].”
BackgroundSynthesis and Evaluation of the Antifungal and Toxicological Activity of Nitrofuran Derivatives
Vaso, C. O., Pandolfi, F., Bila, N. M., Vita, D. D., Bortolami, M., Mendes‐Giannini, M. J. S., Tudino, V., Costi, R., Costa-Orlandi, C. B., Fusco‐Almeida, A. M., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030593 · Cited by 9
“It is a mycosis considered to have a worldwide distribution, already having been described in all continents except for Antarctica [1,27].”
BackgroundTLR Signaling Rescues Fungicidal Activity in Syk-Deficient Neutrophils
Viens, A. L., Timmer, K. D., Alexander, N. J., Barghout, R., Milosevic, J., Hopke, A. R., Atallah, N. J., Scherer, A. K., Sykes, D. B., Irimia, D., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100599 · Cited by 9
Estimated Incidence and Prevalence of Serious Fungal Infections in Morocco
Lmimouni, B., Hennequin, C., Penney, R. O. S., & Denning, D. W. (2022) · Journal of Fungi · doi:10.3390/jof8040414 · Cited by 11
Self-citationVeríssimo, C., Toscano, C., Ferreira, T., Abreu, G., Simões, H., Diogo, J., Carvalho, D., Santiago, F., Lima, A., Queirós, A. M., et al. (2022) · Microorganisms · doi:10.3390/microorganisms10051010 · Cited by 8
Ma, H., Qian, A., Zheng, Y., Meng, X., Wang, T., Zhang, Y., Sun, L., Zou, F., Zhao, B., Zhang, S., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02227 · Cited by 12
Brown, A. C., Mead, M. E., Steenwyk, J. L., Goldman, G. H., & Rokas, A. (2022) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2022.802494 · Cited by 9
“Invasive aspergillosis (IA), a human disease caused by members of the fungal genus Aspergillus, is responsible for >400,000 cases worldwide per year with a mortality rate between 50-95% (Bongomin et al., 2017).”
BackgroundBereźnicka, A., Mikolajczyk, K. P., Czerwiński, M., & Kaczmarek, R. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.958653 · Cited by 8
Porphycenes as broad-spectrum antimicrobial photosensitizers. Potentiation with potassium iodide
López, E. J. G., Santamarina, S. C., Alvarez, M. G., et al. (2022) · Journal of Photochemistry and Photobiology A Chemistry · doi:10.1016/j.jphotochem.2022.114288 · Cited by 8
Santiago, M. G., da Silva, C. D., de Souza, B. M., Assis, B. R. D., Pinto, P. N., Keller, K. M., Vilela, R., de Oliveira, C. S. F., & Goulart, G. A. C. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122619 · Cited by 9
How to lose resistance to Aspergillus infections
Gangneux, J., Hoenigl, M., & Papon, N. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.01.008 · Cited by 7
Suprewicz, Ł., Skłodowski, K., Walewska, A., Deptuła, P., Sadzyńska, A., Eljaszewicz, A., Moniuszko, M., Janmey, P. A., & Bucki, R. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04082-22 · Cited by 9
Diagnostic options for pulmonary fungal diseases in Africa
Mushi, M. F., ZAKI, S. M., Penney, R. O. S., Bamba, S., Kuate, M. P. N., Éric, K. I., Amona, F. M., Werkneh, S., Ceesay, B., Dibba, B., et al. (2023) · ERJ Open Research · doi:10.1183/23120541.00397-2022 · Cited by 10
“Sub-Saharan Africa has the largest burden of pulmonary TB globally [33], with 16 of the 30 high-burden countries located there [34].”
Self-citationSystemic and topical antifungal drugs
Borah, P., Hazarika, S., Sharma, D., Venugopala, K. N., Chopra, D., Al‐Shar’i, N. A., Hemalatha, S., Shakya, A. K., Acharya, P. C., & Deb, P. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90575-6.00002-8 · Cited by 12
Luther, C. H., Brandt, P., Vylkova, S., Dandekar, T., Müller, T., & Dittrich, M. T. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1108235 · Cited by 10
“Invasive candidiasis poses a major threat with more than ~700,000 cases worldwide (Bongomin et al., 2017) and C.”
BackgroundHamed, K. A., Engelhardt, M. F., Kovanda, L. L., Huang, J. J., Yan, J. L., & Aram, J. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-31788-1 · Cited by 8
The role of methionine synthases in fungal metabolism and virulence
Scott, J., & Amich, J. (2023) · Essays in Biochemistry · doi:10.1042/ebc20230007 · Cited by 11
Current Status and Trends in Alternative Models to Study Fungal Pathogens
Junqueira, J. C., & Mylonakis, E. E. (2019) · Journal of Fungi · doi:10.3390/jof5010012 · Cited by 8
Dermatomycoses in the Israeli defense forces—Epidemiological and clinical aspects
Ravid, A., Michael, F., Cohen, D., & Segal, E. (2019) · Mycoses · doi:10.1111/myc.13015 · Cited by 10
Aspergillosis in Humans and Animals
Seyedmousavi, S. (2019) · Springer eBooks · doi:10.1007/978-981-13-9435-5_4 · Cited by 11
Nagy, M., Szemán-Nagy, G., Kiss, A., Nagy, Z. L., Tálas, L., Racz, D., Majoros, L., Tóth, Z., Szigeti, Z. M., Pócsi, I., et al. (2020) · Molecules · doi:10.3390/molecules25040903 · Cited by 10
Anti-fungal study on aqueous and ethanolic leaves extracts of Piper sarmentosum
Ibrahim, M., & Emlee, A. M. (2020) · Matrix Science Pharma · doi:10.4103/mtsp.mtsp_3_20 · Cited by 8
Barreales, E. G., Rumbero, Á., Payero, T. D., de Pedro, A., Jambrina, E., & Aparicio, J. F. (2020) · Antibiotics · doi:10.3390/antibiotics9070413 · Cited by 9
“In the last few decades, there has been a continuous rise in the incidence of fungal infections with deadly results [1].”
BackgroundIs an azole‐resistant Aspergillus hotspot emerging in South‐East Asia?
van Rhijn, N., & Denning, D. W. (2021) · Environmental Microbiology · doi:10.1111/1462-2920.15710 · Cited by 8
Self-citationDiniz-Lima, I., da Fonseca, L. M., dos Reis, J. S., Santos, M. A. R. D. C., da Costa, K. M., Santos, C. A. D. N., Barcelos, P. M., Pinto, K. G., Filardy, A. A., de Lima, M. E. F., et al. (2022) · Medicines · doi:10.3390/medicines9060037 · Cited by 9
“In addition to the species of the genus Cryptococcus, debilitated individuals are also affected by several other genera of fungi [15], such as the genus Aspergillus, which is responsible for cases of severe pneumonia in immunologically weakened hosts, promoting a high mortality rate and high number of hospitalizations…”
BackgroundDesign, Synthesis and Antifungal Evaluation of Novel Pyrylium Salt In Vitro and In Vivo
Zhang, Y., Li, Q., Chao, W., Qin, Y., Chen, J., Wang, Y., Liu, R., Lv, Q., & Wang, J. (2022) · Molecules · doi:10.3390/molecules27144450 · Cited by 7
“Despite advances in antifungal therapy, invasive fungal infection remains the major cause of morbidity and death among immunocompromised patients [7].”
BackgroundSalah, H., Houbraken, J. A. M. P., Boekhout, T., Almaslamani, M., & Taj‐Aldeen, S. J. (2022) · Medical Mycology · doi:10.1093/mmy/myac098 · Cited by 8
Martínez‐Campos, Z., Elizondo-Zertuche, M., Hernández‐Núñez, E., Hernandez‐Fernandez, E., Robledo-Leal, E., & López-Cortina, S. (2023) · Molecules · doi:10.3390/molecules28103995 · Cited by 7
Mini-review antimicrobial smart materials: the future’s defense against wound infections
Monroe, M. B. B., & Fikhman, D. A. (2023) · Frontiers in Biomaterials Science · doi:10.3389/fbiom.2023.1285386 · Cited by 7
Zhang, S., Geng, Y., Wei, B., Lu, Y., He, L., Zhao, F., Zhang, J., Qin, Z., & Gong, J. (2023) · Journal of Fungi · doi:10.3390/jof10010028 · Cited by 7
“Pathogenic fungi have become relevant threats to human security [1,2].”
BackgroundSAR study of N′-(Salicylidene)heteroarenecarbohydrazides as promising antifungal agents
Sun, Y., Kim, S., Shin, S., Takemura, K., Matos, G. S., Lazzarini, C., Haranahalli, K., Zambito, J., Garg, A., Poeta, M. D., et al. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117610 · Cited by 9
Curcumin and Curcumin Derivatives for Therapeutic Applications: In vitro and In vivo Studies
Gupta, B., Sharma, P. K., Malviya, R., et al. (2024) · Current Nutrition & Food Science · doi:10.2174/0115734013281379231228061438 · Cited by 7
Influence of Zinc on Histoplasma capsulatum Planktonic and Biofilm Cells
Pires, A. C. M. D. S., Carvalho, A. R., Vaso, C. O., Mendes‐Giannini, M. J. S., Singulani, J. D. L., & Fusco‐Almeida, A. M. (2024) · Journal of Fungi · doi:10.3390/jof10050361 · Cited by 7
“Histoplasmosis is a fungal respiratory disease with a high incidence and mainly affects immunocompromised individuals [1–3].”
BackgroundNeto, J. F. D. C., Rocha, W. P. D. S., Makris, G., Sandoval‐Denis, M., Hagen, F., Crous, P. W., & Chaves, G. M. (2024) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0012247 · Cited by 9
Doshi, A., Prabhakar, B. R., & Wairkar, S. (2024) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-024-06815-w · Cited by 7
“Dermatophytes are a group of fi lamentous fungi invading the keratinized tissue like the epidermis, nails, and hairs [1].”
BackgroundAntifungal Efficacy of Terpenes and Mechanism of Action Against Human Pathogenic Fungi
Raj, N., Parveen, P., Khatoon, S., & Manzoor, N. (2024) · Springer eBooks · doi:10.1007/978-981-97-5165-5_11 · Cited by 8
A novel pH-responsive monomer inhibits Candida albicans via a dual antifungal mode of action
Li, H., Shi, Y., Chen, H., Liang, J., Zhang, S., Li, B., Chen, J., Li, M., Peng, X., Zhou, X., et al. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00851k · Cited by 8
Şanlı, K., Arslantaş, E., Ceylan, A. N., Öncel, B., Yıldırgan, D. Ö., & Karagenç, A. Ö. (2024) · Diagnostics · doi:10.3390/diagnostics14202343 · Cited by 8
“The microbiological and clinical features of invasive Candida infections vary according to different geographical regions, hospitals, clinics and age [1].”
BackgroundNakamura, T., Yoshinouchi, T., Okumura, M., Yokoyama, T., Mori, D., Nakata, H., Yasunaga, J., & Tanaka, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-78815-3 · Cited by 13
Cruz, A. P., Bergamini, B. V. S. D. A., Pessoa, I. S., Cutrim, T. A. D. S., dos Santos, T. C., dos Santos, M. C., Fonseca, V. R., Romão, W., Scherer, R., Endringer, D. C., et al. (2024) · Brazilian Journal of Microbiology · doi:10.1007/s42770-024-01591-9 · Cited by 9
“T. rubrum , C. albicans , and C. parapsilosis are notable pathogens that play a crucial role in developing various diseases [5 , 6].”
Clinical evaluation of droplet digital PCR in suspected invasive pulmonary aspergillosis
Liu, Y., Tang, Q., Tang, S., Huang, H., Kou, L., Zhou, Y. Y., Ruan, H., Yuan, Y., He, C., & Ying, B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120153 · Cited by 8
Nanostructured Lipid Carriers: A Revolutionary Approach in Antifungal Drug Delivery
Mahapatra, M., Mohapatra, S., & Jena, G. K. (2025) · Biomedical Materials & Devices · doi:10.1007/s44174-025-00277-6 · Cited by 9
When to suspect and how properly early detect and treat patients with endemic mycoses
Colombo, A. L., Pietrobom, P. M. P., Santos, D. W. D. C. L., & Cáceres, D. H. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101348 · Cited by 8
Sporothrix is neglected among the neglected
Matute, D. R., & Teixeira, M. D. M. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1012898 · Cited by 9
“Annually, close to 1 billion people are affected by mycoses [1,3].”
Rozaliyani, A., Setianingrum, F., Isbaniah, F., Agustin, H., Handayani, R. R. D., Syahrir, R., Pratiekauri, S., Adawiyah, R., Setiastuti, H., Erhamza, M. N., et al. (2025) · Journal of Fungi · doi:10.3390/jof11050329 · Cited by 9
Self-citationChromoblastomycosis: a contemporary review of a neglected disease
Tuckwell, W., Yesudian, P. D., & Chandler, D. J. (2025) · Clinical and Experimental Dermatology · doi:10.1093/ced/llaf201 · Cited by 12
Mechanisms of aureobasidin A inhibition and drug resistance in a fungal IPC synthase complex
Wu, X., Gong, X., & Xie, T. (2025) · Nature Communications · doi:10.1038/s41467-025-60423-y · Cited by 15
Ahmad, S., Boekhout, T., Al‐Hatmi, A. M. S., Al‐Harrasi, A., Khateb, A. M., Dhaheri, F. A. A., Shuraym, H. B., Thomsen, J., Alobaid, K., Asadzadeh, M., et al. (2025) · Mycoses · doi:10.1111/myc.70073 · Cited by 12
Athavale, J., Gopalakrishnan, R., Krishna, V., Sethuraman, N., Nambi, S., Sridharan, S., Balaguru, P., Balakrishnan, L., & Ramasubramanian, V. (2025) · Mycopathologia · doi:10.1007/s11046-025-00974-2 · Cited by 9
“The global incidence rate of invasive candidiasis (IC) ranges from 2 to 14 cases per 100,000 persons and the prevalence in hospitalized patients ranges from 250,000 to 700,000 people per year [1, 2].”
Woods, M., McAlister, J. A., Segeren, L., da Silva, M. B., Deyarmin, J. S., Hakimi, A., Hermanson, D. J., Richter, J., Samra, S. N., & Geddes‐McAlister, J. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.101083 · Cited by 6
Sehgal, I. S., Agarwal, R., Dhooria, S., Prasad, K. T., Muthu, V., Aggarwal, A. N., Rudramurthy, S. M., Garg, M. K., & Chakrabarti, A. (2025) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(25)00537-7 · Cited by 9
Fan, T., Li, Z., Zhao, Z., Liu, B., Fan, C., Wang, T., Yang, M., Li, Y., Lin, M., & Lin, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-29061-8 · Cited by 9
De-la-Pinta, I., Marcos‐Arias, C., Sevillano, E., Eraso, E., & Quindós, G. (2026) · Microorganisms · doi:10.3390/microorganisms14020367 · Cited by 7
“Historically infection control strategies have primarily focused on bacterial pathogens [1]; however, there has been a marked increase in invasive mycoses in recent years [2,3].”
Aspergilose e mucormicose – micoses sistêmicas de importância em COVID-19: Artigo de revisão
Tavares, R. M., Leite, C. E. A., Tavares, R. M., Oliveira, P. L., & de Quental, O. B. (2021) · Research Society and Development · doi:10.33448/rsd-v10i7.17101 · Cited by 15
Hu, N., Mo, X.-M., Xu, S., Tang, H., Zhou, Y., Li, L., & Zhou, H. (2022) · Innate Immunity · doi:10.1177/17534259221080543 · Cited by 7
“Among these, 150 million people suffer from severe infections.(6) Candida albicans is the most common pathogenic species that accounts for 21–68% of invasive candidiasis in different countries.”
BackgroundBiofungicides for Improvement of Potato (Solanum tuberosum L) Production
Ehiobu, J. M., Idamokoro, E. M., & Afolayan, A. J. (2022) · Scientifica · doi:10.1155/2022/1405900 · Cited by 10
Application of the Mutant Libraries for Candida albicans Functional Genomics
Wang, R., Liu, J., Liu, Y., Lv, Q., & Yan, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012307 · Cited by 11
“Candida albicans is one of the most prevalent fungal pathogens in human beings causing infectious diseases ranging from superficial mucosal and dermal infections to life-threatening systemic infections with a mortality rate of nearly 40% [1,2].”
BackgroundFungal calcineurin complex as an antifungal target: From past to present to future
Li, X., Zhang, C., & Lü, L. (2022) · Fungal Biology Reviews · doi:10.1016/j.fbr.2022.10.003 · Cited by 8
Sivaraman, D., Selvadoss, P. P., & Manoharan, S. S. (2022) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-022-04207-w · Cited by 9
“1 3 significant medical challenge to physicians and health organizations throughout the world [35].”
BackgroundAbdul-Hammed, M., Adedotun, I. O., Adegoke, H. M., Olajide, M., Osilade, O. J., Afolabi, T. I., & Abdul-Hammed, A. I. (2022) · Majalah Obat Tradisional · doi:10.22146/mot.77380 · Cited by 8
“Fungal infections affect a wide diversity of populations and are caused by many different fungal pathogens from various sources (Bongomin et al., 2017).”
BackgroundSeegers, C., Lee, D. J., Zarnovican, P., Kirsch, S. H., Müller, R., Haselhorst, T., & Routier, F. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031851 · Cited by 10
“One of the most lethal fungi is Aspergillus fumigatus, which causes several diseases including allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), and invasive aspergillosis (IA) [1].”
The role of the Mediator complex in fungal pathogenesis and response to antifungal agents
O’Connor-Moneley, J., Alaalm, L., Moran, G. P., & Sullivan, D. J. (2023) · Essays in Biochemistry · doi:10.1042/ebc20220238 · Cited by 11
Shah, P., Bhargava, S., Chakrabarty, S., Damodaran, R. T., Saikia, P. K., Shenoy, M., & Bangale, N. (2023) · IP Indian Journal of Clinical and Experimental Dermatology · doi:10.18231/j.ijced.2023.001 · Cited by 16
Chen, X., Lei, W., Meng, H., Jiang, Y., Zhang, S., Chen, H., Du, M., & Xue, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161642 · Cited by 8
“It is estimated that 250,000 cases of IA occur worldwide each year, with a mortality rate of 30%–80% (4).”
Background
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.